Immunotherapy for endometrial and uterine cancer — and the one test that decides it

Most patients are not. Endometrial cancer is usually found while it is still confined to the uterus, and surgery, sometimes followed by radiation, is the treatment that does the work. Immunotherapy is not part of that plan. It has a defined role in advanced or recurrent disease, and there the mismatch repair result usually decides it.

Leading with the limit is unusual for a cancer clinic, so it is worth explaining why this page does it. Endometrial cancer is the most common cancer of the female reproductive organs in much of the world, and numbers are rising in India alongside obesity, diabetes and later menopause. Most women notice it early, because the cardinal sign — bleeding after menopause, or bleeding between periods — is hard to ignore. Found at that point, the cancer is usually still inside the uterus, and the plan is an operation, not an infusion.

So a large number of women are told they have a cancer for which immunotherapy is being discussed everywhere, and are then offered something else entirely. That is not a downgrade. It is the treatment that matches the stage, and adding a checkpoint inhibitor where the evidence does not support it adds side effects and cost with certainty, and benefit only in theory.

Immunotherapy on this page means immune checkpoint inhibitors. They do not attack the tumour directly. They aim to release a brake that cancer cells use to switch off the immune cells sent to deal with them. That approach only works where the immune system has something to recognise — which is exactly why one particular laboratory result matters so much in this disease, and why it is the subject of the next section.

One point of vocabulary. “Uterine cancer” is often used loosely. Cancers arising from the lining of the uterus are endometrial cancers, and that is what almost all of this page describes. Cancers arising from the muscle wall are uterine sarcomas — a rarer and quite different disease, where checkpoint inhibitor immunotherapy is not established treatment outside a clinical trial or a specific biomarker result. Check which one your report names before you read any further.

This page describes treatment classes, not specific medicines or brands, and it recommends no treatment. At CION, immunotherapy is given as day care at our centres when it is genuinely indicated, response-assessment PET-CT is coordinated at our partner imaging centres, and every plan is set by a tumour board rather than by one doctor. Any cost figure discussed with you is indicative, as of August 2026, and is confirmed in writing before treatment starts. If you are at the very beginning, our overview of immunotherapy at CION Cancer Clinics explains how the treatment is delivered and what a day-care visit involves.

In advanced or recurrent endometrial cancer, largely yes. A mismatch repair deficient (dMMR) or MSI-high result is the group where checkpoint inhibitor immunotherapy has the clearest defined role. A proficient (pMMR) or microsatellite stable result does not close the door completely, but it changes which combination is considered.

Around a quarter to a third of endometrial cancers are mismatch repair deficient, which makes this one of the few cancers where a large minority of patients carry the result that matters most. Hold the table below next to your own histopathology report and find the line that matches it.

MMR staining and MSI testing measure the same repair defect in two different ways, which is why the results usually agree. Where loss of MLH1 is reported, a further laboratory step is normally done before anyone concludes the defect was inherited. Result bands and thresholds here follow NCCN, ESMO and ESGO patient-education guidance current in August 2026, and guidance does change. A biomarker result describes the tumour, not a prediction about you as an individual. If your cancer is of the cervix rather than the uterus, the rules are different again — see immunotherapy for cervical cancer, where stage carries more weight than biomarker status.

Being eligible is not the same as being certain to benefit. Immunotherapy helps in a proportion of the patients who receive it, and no test available today can tell an individual in advance which group she will be in.

It aims to release a brake that cancer cells use to switch off your immune cells. In mismatch repair deficient or MSI-high advanced disease, guideline bodies describe meaningful disease control in a substantial proportion of patients, sometimes lasting a long time. It does not work for everyone, and no available test predicts an individual result.

There is a reason the dMMR group stands out, and it is worth understanding rather than just accepting. A cell with a broken mismatch repair system copies its DNA badly and accumulates a very large number of mutations. Those mutations produce abnormal proteins on the surface of the cancer cell. Abnormal proteins are what the immune system is built to notice. So a dMMR tumour is, in effect, a more visible target — and releasing the brake on the immune cells that have already found it is more likely to achieve something.

In practice, benefit shows up as scans that stay stable for longer, or tumours that shrink and stay smaller than chemotherapy alone would have kept them. In a proportion of patients that control lasts. In others there is no change at all, and the treatment is stopped and something else is planned. Both outcomes are ordinary and neither is anybody’s fault.

You will not find survival figures on this page. Numbers taken from trial populations describe a group, not a person, and quoting them to someone deciding on treatment is misleading in both directions. What is fair to expect from your oncologist is a plain account of what the treatment is intended to achieve in your specific situation, how response will be assessed, and the point at which it would be stopped.

The cost side is real too. Checkpoint inhibitors can inflame healthy organs — the thyroid, the gut, the lungs, the liver, occasionally the heart. Thyroid changes are among the more common ones in this treatment class and are usually manageable once found, which is exactly why blood tests are repeated before cycles rather than only when someone feels unwell. Anyone starting this treatment is given a symptom card and a number to call, and told to use it rather than wait for the next appointment.

One thing that is not optional: effective contraception is required throughout treatment and for a defined period afterwards, because these medicines can harm a developing baby. Endometrial cancer is increasingly diagnosed in women before menopause, so this conversation applies to more patients than it once did — our page on contraception during immunotherapy and why it is non-negotiable sets out what is expected and for how long.

Four steps, in this order. Staining for the four repair proteins is run on tissue already removed at biopsy or surgery. MSI or sequencing follows where the staining is unclear. Loss of MLH1 triggers one further laboratory step before any inherited cause is considered. Fitness and autoimmune history are reviewed last.

1. 1

   Staining on the tissue you have already given

   The pathologist stains the sample for the four mismatch repair proteins — MLH1, PMS2, MSH2 and MSH6. If all four are present, the report says proficient, or pMMR. If one or more is missing, it says deficient, or dMMR. This runs on the block already stored from your biopsy or hysterectomy, so it usually needs no fresh procedure, and it typically takes a few working days.

2. 2

   MSI or sequencing, where staining is unclear

   Where the staining is equivocal, or where a wider panel is being run anyway, a DNA-based microsatellite instability test or a sequencing panel can be used instead. That panel may also report tumour mutational burden. One reliable result is normally enough; running every test on every patient is not the aim, and no test should be ordered that will not change a decision.

3. 3

   If MLH1 is the protein that is missing

   Loss of MLH1 is most often an acquired change in the tumour itself rather than something inherited, so a further laboratory step is done to distinguish the two before anyone is referred for genetic testing. Where an inherited cause remains possible, a referral for counselling follows, because Lynch syndrome affects screening advice for blood relatives as well as for you. That is a family conversation, and it deserves a proper appointment.

4. 4

   Fitness, organ function and autoimmune history

   Before any checkpoint inhibitor is started, blood tests check kidney, liver and thyroid function. Your team also reviews existing autoimmune conditions, ongoing steroid use, transplant history and any other condition affecting the immune system, because these change the risk of immune-related side effects and sometimes rule the treatment out altogether.

Biomarker testing costs a small fraction of what a treatment plan costs, and it is the step that decides whether the expensive conversation is even relevant — which is why skipping it is a false economy. Any figure quoted to you for testing or for treatment is indicative, as of August 2026, and is given in writing before anything is sent or started; our page on the cost of immunotherapy for breast and gynaecological cancers explains what drives the number and which schemes may cover part of it. If children are still a question for you, raise it before the first cycle rather than after — see fertility and pregnancy on immunotherapy for what is known, what genuinely is not, and what can be arranged in advance.

It means your stage is being treated the way guidelines recommend for it. Surgery, radiation and chemotherapy are established treatments for endometrial cancer, chosen by stage and by risk of recurrence. Not being offered immunotherapy is not a sign that your options are limited or that your care is somehow lesser.

Families often arrive having read that immunotherapy is the newest treatment, and conclude that anything else must be second best. That is not how cancer treatment works. The right treatment is the one matched to the stage and the biology in front of you. In endometrial cancer specifically, surgery early is the step that carries the most weight in the whole plan, and time spent chasing a treatment your stage does not call for is time that plan is not being completed.

There is one thing worth doing even when the answer is no. Ask for the mismatch repair result to be on record. If the cancer never comes back, it costs you nothing. If it does come back years later, having that result already in the file can save weeks at the point when weeks matter, and it may have flagged a family risk in the meantime.

• Ask which stage you have, in plain words, and ask for it written on your consultation summary.
• Ask whether your specimen was tested for MMR or MSI — and if not, ask for it to be run on the stored tissue.
• If the result is dMMR, ask whether a Lynch syndrome assessment has been arranged for you and your relatives.
• Ask whether immunotherapy is an option at your stage — yes or no, and why.
• If no, ask which treatment is doing the main work in your plan, and how long the whole course runs.
• Ask for the estimated cost of the full plan — indicative, as of August 2026, and in writing.
• Ask whether a scheme such as Aarogyasri, CGHS, ECHS or ESI, or your insurance policy, covers any part of it.

CION is a woman-headed organisation and our teams see endometrial cancer constantly, including many women who put post-menopausal bleeding down to something else for months before coming in. Every consultation is 45 minutes, every plan goes to a tumour board, and no test is ordered that will not change a decision. If you have been advised immunotherapy elsewhere and cannot see which row of the table above you are on, that is exactly the question a second opinion answers.

Most of the confusion about immunotherapy in endometrial cancer comes from not knowing what your own report says. Once you do, these four pages cover the questions that follow, whichever way the result went.

• Fertility and Pregnancy on Immunotherapy — what is known and what is genuinely not known, and what can be arranged before treatment starts rather than after. Relevant to more endometrial cancer patients than it once was.
• Contraception During Immunotherapy: Why It Is Non-Negotiable — what is required, for how long after the last cycle, and why this is one instruction that carries no flexibility.
• Cost of Immunotherapy for Breast and Gynaecological Cancers — what actually drives the figure, why one cycle is a misleading unit, and which schemes and policies may cover part of a plan.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

If you would rather not work through this alone, bring your histopathology and staging reports to a consultation. Forty-five minutes with a medical oncologist, and a tumour board review afterwards, will tell you which row of the table you are on and what follows from it.

This page is general information and does not replace a consultation. It describes treatment classes only, not specific medicines or brands, and it recommends no treatment. Eligibility criteria, molecular groups and biomarker thresholds are drawn from NCCN, ASCO, ESMO and ESGO patient-education guidance current in August 2026 and can change; no outcome or survival figure of any kind is stated or implied. Every decision about your treatment belongs with your own treating team.

Get a second opinion on your endometrial cancer plan

Free, written, and reviewed by our tumour board — so you know why each treatment is in your plan, and why the others are not.